Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.
Cancer
May 02, 2013 |
not rated yet |
0
Researchers identify critical metabolic alterations in triple-negative breast cancer cells
Researchers at Fox Chase Cancer Center have identified a host of small molecules critical to metabolism in cells of triple-negative breast cancer—one of the least understood groups of breast cancer. These molecules, called ...
Cancer
Apr 09, 2013 |
not rated yet |
0
Changing shape makes chemotherapy drugs better at targeting cancer cells
(Medical Xpress)—Bioengineering researchers at University of California, Santa Barbara have found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to ...
Cancer
Feb 27, 2013 |
5 / 5 (3) |
0
|
Treatment targeting PI3K may delay resistance to anti-HER2 therapy in breast cancer patients
Patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens.
Cancer
Jan 23, 2013 |
not rated yet |
0
SABCS: no benefit in extending trastuzumab in HER2 breast CA
(HealthDay)—For patients with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer, one year of adjuvant trastuzumab should remain the standard of care, according to a study ...
Cancer
Dec 07, 2012 |
not rated yet |
0
Heart failure in older breast cancer patients linked to medication
Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin), Yale School of Medicine researchers report ...
Cardiology
Nov 14, 2012 |
not rated yet |
0
|
Adverse prognostic factor ID'd in operable breast cancer
(HealthDay)—For women with operable breast cancer, moderate immunohistochemical expression of human epidermal growth factor receptor (HER)-2 (2+) without amplification of HER-2 (HER-2 2+/HER-2−) is an adverse prognostic ...
Cancer
Oct 30, 2012 |
not rated yet |
0
New findings on optimal duration of trastuzumab therapy for women with HER2+ early breast cancer
New studies that advance understanding of the optimal duration of therapy with the targeted cancer drug trastuzumab were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Cancer
Oct 01, 2012 |
not rated yet |
0
Are too few women being offered breast-conserving treatment?
Two new studies presented at the ESMO 2012 Congress in Vienna, Austria show how improvements in breast cancer treatments are making it possible for more women to conserve their breasts following therapy, but raise concerns ...
Cancer
Sep 30, 2012 |
not rated yet |
0
More heart problems with two chemo drugs for breast cancer
Women who have breast cancer and are treated with two chemotherapy drugs may experience more cardiac problems like heart failure than shown in previous studies, according to a new Cancer Research Network study by Group Health ...
Cancer
Aug 30, 2012 |
not rated yet |
0
Researchers identify mechanism that makes breast cancer invasive
A new study has identified a key mechanism that causes breast cancer to spread. The research, published by Cell Press on March 30th in the journal Molecular Cell, enhances our knowledge about the signals that drive cancer ...
Cancer
Mar 29, 2012 |
not rated yet |
0
Enhancing the effectiveness of a breast cancer treatment
Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. ...
Cancer
Feb 13, 2012 |
5 / 5 (1) |
0
Studies help clarify the role of lapatinib and trastuzumab in treating HER2 positive breast cancer
In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. ...
Cancer
Jan 16, 2012 |
5 / 5 (2) |
0
|
Dual HER2 blockade significantly extends progression-free survival
Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who ...
Cancer
Dec 08, 2011 |
not rated yet |
0
Phase II study shows new cancer drug combination significantly delays breast cancer progression
The first randomised trial to investigate the use of trastuzumab emtansine (T-DM1) – an antibody-guided drug – for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast ...
Cancer
Sep 25, 2011 |
not rated yet |
0
